Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 47c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of $0.32, $0.47 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
• Qualcomm unveils Dragonfly CPU, signs Meta as first data center customer